The concomitant use of proton pump inhibitors and BRAF/MEK inhibitors in metastatic melanoma.
Florence PoizeauFrédéric BalussonFlorian LemaitreCamille TronMarc PrachtDavid RussoMonica DinulescuThierry LesimpleEmmanuel OgerAlain DupuyPublished in: The British journal of dermatology (2023)
In a population-based cohort of patients with advanced melanoma, the concomitant use of PPIs and BRAF/MEK inhibitors was not associated with worse outcome.